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Effectiveness of current therapy of bacterial vaginosis 
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Abstract: The study was conducted in order to evaluate effectiveness of the treatment of bacterial 
vaginosis (BY) with different therapeutic regimes according to recommendations of the World Health 
Organi~ion ~WHO). During a one-year period (February 2000-February 2001) the Sexually 
Transmatted Dascases (SID) Center was visited by 482 women aged 14-51. The diagnosis of BY was 
established by standard methods: Amsel's clinical criteria and Gram stain of vaginal discharge. The 
first-line treatment was oral Metronidazole 2g single dose. Second line was Metronidazole 500mg 
twice daily orally for 7 days or oral Clindamycin 300 mg twice daily for seven days. BV was 
confirmed in 74 women (15.4%). Most often it was observed in women aged 17-30 years of age. 
Thiny-threc (44.6% of total) were young women 14-21 years of age. Thirty-one (42%) women 
rectived a follow-up examination and of those, II (38. 7%) needed a repeat treatment for BV due to 
unsatisfactory results of this treatment. It is concluded that treatment of BY with standard methods 
was not always effective with no significant difference between women under 21 years and older 
women found in regards to response to treatment. Besides antibiotic treatment, the so-called 
Probiotics (Lactobacillus acidophilus) can be taken into consideration as an alternative treatment. 
Additional research about the therapeutic effect of this type of drugs is needed. 
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INTRODUCTION 
Bacterial vaginosis (BV) is one of the most 
common infections of the lower genital 
tract in women. This condition can be 
characterised by a decrease or elimination 
of H20 2-producing lactobacilli and an 
overgrowth of mixed vaginal flora of 
aerobic, anaerobic and micro-aerophilic 
species (Gardnerella vaginalis, Mobiluncus, 
Bacteroides, Prevotella, Mycoplasma) in 
very large numbers. BV is connected with 
an increased risk of developing a number of 
gynecologic and obstetric complications 
such as premature delivery, premature 
rupture of amniotic membranes, and pelvic 
inflammations. Recently, BV has been 
found to promote HIV transmission and the 
advent of cervical cancer. The cause of the 
appearance of this disorder is unknown. As 
a result, the disease cannot be prevented 
(1,2). 
MATERIAL AND METHODS 
Patients who took part in the study came to 
the Sexually Transmitted Diseases Center 
of the University Hospital of Obstetrics and 
Gynaecology "Maychin Dom". The study 
was conducted between February 2000 -
February 2001 with 482 women examined. 
The study includes an interview (history), a 
gynecological examination, and a 
microbiological evaluation. A file was 
created for every visitor to the center, 
including identification number, age, 
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number of visits, previous sexually 
transmitted diseases (STDs) and if she 
belonged to a risk group (sexual workers, 
homosexual, homeless, intravenous drug 
users). 
The gynecological examination includ-
ed a speculum survey and an evaluation of 
the vaginal discharge - quantity, smell, 
color, and presence of purulent discharge 
from the cervix. The acidity of the vagina 
was measured with a pH-paper (Merck~. 
Using a cotton stick, a sample was taken 
from the lateral vaginal wall and spread 
onto separate slides. On the first slide the 
vaginal secretions were mixed with 10% 
KOH to perform the amine test, on the 
second one - with one drop of saline to 
make a wet mount. The third smear was 
fixed on a spirit-lamp and Gram-stained. 
The preparations were then investigated 
under a light microscope with a magnif-
ication of 400 and for the colour smear -
using an immersion technique ·and a 
magnification of 1000. A score system for 
evaluation of the risk of developing 
cervicitis was applied to patients with 
vaginal discharge (Table I). If the score 
was two points or more these patients were 
at high risk (for gonococci and chlamydia 
Trachomatis infection) and a therapeutic 
scheme was applied. 
Table 1. Risk score in patients with vaginal 
discharge. Patients with 2 or more points 
are considered high risk for cervicitis 
Symptomatic partner 2 pts. 
(urethral discharge) 
- No constant partner I pt. 
and/or age under 20 years 
- More then one partner I pt. 
during the last 3 months 
- New partner during the I t p. last 3 months 
The diagnosis of bacterial vaginosis was 
based upon Amsel's clinical criteria and the 
results of Gram's staining according to 
Nugent's score. The drugs Metronidazole 
and Clindamycine orally were used in 
patients having BV according to the 
therapeutic regimes described in Table 2. 
An alternative regime was used in cases of 
failure of treatment with Metronidazole 2 g, 
cases of allergy to the drug. Clindamycine 
was the drug of choice in pregnant women. 
Table 2. Therapeutic regimes used in 
treatment of B V. 
First drug of choice 
Metronidazole 
2glsingle dose, 
orally 
RESULTS 
Alternative regimes 
Metronidazole 500 
mg twice daily for 
7 days, orally 
Clindamycin 300 
mg twice daily for 
7 days, orally 
Out of 482 women, the diagnosis of 
bacterial vaginosis was made in I5.4% (74 
women). Thirty-three patients (46.6%) were 
under 2 I years of age. Twenty three percent 
(17 women, 8 under 2Iyears and 9 over 21 
years of age) of the patients with BV had 
high-risk sexual behaviour. In 30.0% (22 
women) BV co-existed with other sexually 
transmitted diseases - (Trichomoniasis, 
Condylomata Acuminata, Syphilis Gonorr-
hea). Pelvic inflammatory dis:ase was 
dia?"osed in one case. Thirty-one (42%) 
patients returned to the Center for a follow-
up examination within three weeks of the 
initial visit. In 19 (61.3%) of these cases a 
no~alization of the vaginal pH and a 
h~al~g according to Amsel's and Nugent's 
cnt~n~ were established. (Table 3). No 
statistically significant difference was 
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found between women under 21 and those 
older than 21 years. In 12 (38.7%) patients, 
a repeat treatment for BV was needed 
because of unsatisfactory results of this 
treatment. 
Table 3. Effect of treatment in the different age groups. 
Effect of the women up to 21 years women over 21 years 
treatment A11 women with n=I5 n=16 fo1low-up 
n=31 
Good response of the 10(66.7%) 9 (56.3%) 19 {61.3%) treatment 
Unsatisfactory result 5 (33.4%) 7(43.8%) 12 (38.7%) 
of the treatment 
Table 4. Sexual transmission of BV. 
FOR: 
I. Discovery of G. vaginalis in the urethra 
2. Correlation with the number of sexual partners 30 days before the examination. 
3. Diminishing of the frequency ofBV in monogamy couples 
4. Lack ofBV in virgin girls 
AGAINST: 
I. Bacteria do not persist in the male urethra. 
2. The risk ofBV does not grow with the number of sexual partners. 
3. The frequency of relapse does not diminish after treatment of the partner. 
4. Discovery of BV. in virgin girls 
5. The rectum of women is a reservoir for the microorganisms, associated with BV 
DISCUSSION 
Bacterial vaginosis (BV) is one of the most 
widespread vaginal infections and second in 
frequency in Europe, preceded only by 
vaginal : candidomycosis. Incidence is 
reported to . be anywhere from 4% to 64% 
(3). In our study the incidence of BV in our 
patient population was 15.4%. There are 
many studies of the epidemiology of BV 
that shows a connection to sexual activity, a 
prior existing trichomoniasis or other sex-
ually transmitted diseases, the use of 
contraceptives . and in particular the use of 
intrauterine devices as well as black ethnic 
groups (4). Whether BV is a sexua1ly 
transmitted disease is still an open question. 
In the present study 23% of the women 
with BV had high-risk sexual behaviour 
and in 31.1% the disease was combined 
with other STDs. There are many pros and 
cons for the classification of BV as a 
typical STD. (Table 4). The modem 
concept is that BV has the epidemiology of 
an STD, but it cannot be included in the list 
of the typical STDs (5). The results of 
treatment in the present study showed 
treatment failure in 38.7% of the cases 
(Table 3). Different studies show an 
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effectiveness of Metronidazole and 
Clindamycin therapy ranging from 65% to 
99%, but this is only a short-term result (6). 
Although antibiotic therapy has been shown 
to eliminate BY-associated organisms, there 
is an extremely high recurrence rate, with 
reports up to 50% of patients experiencing 
recurrent infections (7,8). The described 
therapeutic regimens are not sufficiently 
effective and new treatments need to be 
considered. 
Evidence points towards recurrence 
occurring as a result of failure to establish a 
normal flora following antimicrobial 
therapy. Lactobacilli are a major component 
of normal vaginal microflora. They colon-
ize the epithelium and form a defensive 
biofilm, due to their ability to form lactic 
acid, hydrogen peroxide, bacteriocins, 
Acidophylin, and other antimicrobial 
substances (9). Parent and other investigat-
ors report evidence of good therapeutic 
effect after administration of Lactobacillus 
acidophilus for treatment of BV (10,11). 
The application of novel molecular methods 
in combination with appropriate biological 
tests give the opportunity to fmd specific 
strains that confer effect and exhibit 
immunoadjuvant properties (7). The study 
of natural bacteriocinogenic activity and 
Probiotics potential of newly isolated 
vaginal LAB is a condition to develop new 
prep~tions for clinical application. 
Additional studies of the therapeutic effect 
of this type of drugs are needed. 
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